Develops antibody drug conjugates for cancer treatments.
Jun 2026Revenue $0.00/yrExpenses $86.1M/yr
No trendCash runway ≈ 2.7 years from Jun 2026
Figures by year
When will Whitehawk Therapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $0.00 and expenses $86.1M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $7.14M | $122M | −$114M |
| Dec 2024 | $26.0M | $93.4M | −$67.5M |
| Dec 2023 | $24.4M | $96.3M | −$71.9M |
| Dec 2022 | $15.2M | $77.9M | −$62.7M |
| Dec 2021 | $14.0M | $125M | −$111M |
| Dec 2020 | $14.0M | $16.5M | −$2.55M |
| Dec 2019 | $0.00 | $24.4M | −$24.4M |
| Dec 2018 | $20.2M | $31.3M | −$11.2M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.